Transcend Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-364,383
| Closed | -$2.97M | – | 641 |
|
|
2025
Q1 | $2.97M | Buy |
364,383
+470
| +0.1% | +$3.84K | 0.21% | 115 |
|
|
2024
Q4 | $3.43M | Buy |
363,913
+37,059
| +11% | +$349K | 0.25% | 101 |
|
|
2024
Q3 | $3.49M | Sell |
326,854
-3,473
| -1% | -$37.1K | 0.23% | 110 |
|
|
2024
Q2 | $3.28M | Buy |
330,327
+20,005
| +6% | +$198K | 0.24% | 105 |
|
|
2024
Q1 | $3.66M | Buy |
310,322
+344
| +0.1% | +$4.05K | 0.29% | 84 |
|
|
2023
Q4 | $4.4M | Buy |
309,978
+23,474
| +8% | +$333K | 0.39% | 56 |
|
|
2023
Q3 | $3.48M | Buy |
286,504
+359
| +0.1% | +$4.37K | 0.34% | 65 |
|
|
2023
Q2 | $3.59M | Buy |
286,145
+69,686
| +32% | +$875K | 0.34% | 67 |
|
|
2023
Q1 | $2.4M | Buy |
216,459
+773
| +0.4% | +$8.57K | 0.25% | 104 |
|
|
2022
Q4 | $2.63M | Buy |
215,686
+617
| +0.3% | +$7.53K | 0.29% | 87 |
|
|
2022
Q3 | $2.25M | Buy |
215,069
+18,873
| +10% | +$197K | 0.25% | 106 |
|
|
2022
Q2 | $2.11M | Buy |
196,196
+52,975
| +37% | +$569K | 0.22% | 121 |
|
|
2022
Q1 | $1.36M | Buy |
143,221
+1,157
| +0.8% | +$11K | 0.12% | 181 |
|
|
2021
Q4 | $1.64M | Sell |
142,064
-800
| -0.6% | -$9.24K | 0.14% | 162 |
|
|
2021
Q3 | $1.48M | Buy |
142,864
+1,800
| +1% | +$18.6K | 0.13% | 169 |
|
|
2021
Q2 | $1.36M | Sell |
141,064
-4,000
| -3% | -$38.6K | 0.2% | 127 |
|
|
2021
Q1 | $1.43M | Buy |
145,064
+35,209
| +32% | +$348K | 0.17% | 137 |
|
|
2020
Q4 | $2.54M | Buy |
+109,855
| New | +$2.54M | 0.33% | 79 |
|